Company / Capital Returned to Shareholders
CRISPR Therapeutics AG Capital Returned to Shareholders History
FY2018-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$57.0K
FY2018
5-year range
-
FY2018-FY2018
Trend
-
vs FY2017
Sector context
#46 of 52
Health Care
What the data says
CRISPR Therapeutics AG's capital returned to shareholders of $57,000 is lower than 88% of companies in the Health Care sector (FY2018).
Based on SEC 10-K filings.
$57,000 in FY2018.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 52This company $57.0K Sector average $1.4B
▼
-100.0% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $57.0K | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2018 · SEC 10-K · Updated Feb 28, 2026